Advertisement
Singapore markets open in 37 minutes
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Bitcoin USD

    64,385.80
    -2,136.32 (-3.21%)
     
  • CMC Crypto 200

    1,389.55
    -34.55 (-2.43%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Gold

    2,328.60
    -9.80 (-0.42%)
     
  • Crude Oil

    82.74
    -0.07 (-0.08%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • Nikkei

    38,003.63
    -456.45 (-1.19%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Assessing AbbVie’s 2018 Revenue Projections

Assessing AbbVie’s 2018 Revenue Projections

On its third-quarter earnings conference call, AbbVie (ABBV) raised its net revenue guidance for 2018 from its previous projection of $32.5 billion to $32.7 billion. The company also raised its forecast for YoY (year-over-year) operational revenue growth in 2018 from 14.5% to 15.0%. As per AbbVie’s third-quarter earnings conference call, the company expects a favorable revenue impact of less than 1% due to foreign currency fluctuations in 2018.